U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H25NO
Molecular Weight 271.3972
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOMETHORPHAN

SMILES

COC1=CC=C2C[C@@H]3[C@@H]4CCCC[C@]4(CCN3C)C2=C1

InChI

InChIKey=MKXZASYAUGDDCJ-CGTJXYLNSA-N
InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/26226106 | https://www.ncbi.nlm.nih.gov/pubmed/23628523 | https://www.ncbi.nlm.nih.gov/pubmed/24142584

Racemethorphan is racemic mixture of Dextromethorphan and Levomethorphan. Racemethorphan is listed under the Single Convention on Narcotic Drugs 1961 and is therefore listed in the United States as a Controlled Substance, specifically as a Narcotic in Schedule II. Dextromethorphan is a non-narcotic morphine derivative widely used as an antitussive. Dextromethorphan is a cough suppressant in many over-the-counter cold and cough medicines. In 2010, the FDA approved the combination product dextromethorphan/quinidine for the treatment of pseudobulbar affect. Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla of the brain. Levomethorphan is an opioid analgesic of the morphinan family that has never been marketed.

CNS Activity

Curator's Comment: https://www.ncbi.nlm.nih.gov/pubmed/16634036

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The placebo response to citric acid-induced cough: pharmacodynamics and gender differences.
2001
Pharmacological control of cough.
2001 Apr
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.
2001 Apr
Angle closure risk from proprietary medicines.
2001 Apr
Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.
2001 Apr
Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
2001 Apr 15
Characterization of biotransformation enzyme activities in primary rat proximal tubular cells.
2001 Apr 16
A fast and efficient determination of amines and preservatives in cough and cold liquid and suspension formulations using a single isocratic ion-pairing high performance [correction of power] liquid chromatography method.
2001 Aug
CYP2D6 polymorphism in a Mexican American population.
2001 Dec
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin.
2001 Dec
Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
2001 Dec 1
The safety of dextromethorphan in pregnancy : results of a controlled study.
2001 Feb
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
2001 Jan
Separation of cold medicine ingredients by capillary electrophoresis.
2001 Jan
Epidemiologic analysis of prenatal exposure to cough medicines containing dextromethorphan: no evidence of human teratogenicity.
2001 Jan
Terbinafine-associated inhibition of dextromethorphan metabolism in Chinese subjects.
2001 Jan
In vivo effect of clarithromycin on multiple cytochrome P450s.
2001 Jul
Clinical case discussion: anesthesia for Cesarean section in a parturient with a large intrathoracic tumour.
2001 Jun
Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
2001 Jun
Uncompetitive NMDA receptor antagonists potentiate morphine antinociception recorded from the tail but not from the hind paw in rats.
2001 Jun 29
Dextromethorphan is an effective cough suppressant.
2001 May
Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.
2001 May
Effects of dextromethorphan on the seizures induced by kainate and the calcium channel agonist BAY k-8644: comparison with the effects of dextrorphan.
2001 May
Important drugs for cough in advanced cancer.
2001 Nov
Gas chromatographic method using nitrogen-phosphorus detection for the measurement of tramadol and its O-desmethyl metabolite in plasma and brain tissue of mice and rats.
2001 Nov 5
Effects of dextromethorphan on nocturnal behavior and brain c-Fos expression in adolescent rats.
2001 Nov 9
Abuse of Coricidin HBP cough & cold tablets: episodes recorded by a poison center.
2001 Oct 1
Analgesic effects of dextromethorphan and morphine in patients with chronic pain.
2002 Apr
Modulation of human corticomotor excitability by somatosensory input.
2002 Apr 15
Development of a rapid and sensitive high-performance liquid chromatographic method to determine CYP2D6 phenotype in human liver microsomes.
2002 Feb
Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys.
2002 Feb
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity.
2002 Jan
Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation.
2002 Jan
Effect of ketamine, dextromethorphan, and MK-801 on cochlear dysfunction induced by transient ischemia.
2002 Jan
Dextromethorphan can produce false positive phencyclidine testing with HPLC.
2002 Jan
Inhibition kinetics of monoclonal antibodies against cytochromes P450.
2002 Jun
Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.
2002 Jun
Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.
2002 Mar 1
The effects of concomitant administration of theophylline and toborinone on the pharmacokinetics of both compounds in poor and extensive metabolizers via CYP2D6.
2002 May
Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials.
2002 May
Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
2002 May
Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial.
2002 May 11
Semi-automated liquid--liquid back-extraction in a 96-well format to decrease sample preparation time for the determination of dextromethorphan and dextrorphan in human plasma.
2002 May 25
Ubiquitous computing for remote cardiac patient monitoring: a survey.
2008
Effects of common antitussive drugs on the hERG potassium channel current.
2008 Dec
Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice.
2009 Apr 1
Amyotrophic lateral sclerosis.
2009 Feb 3
Characterization of retrieved orthodontic miniscrew implants.
2009 Jan
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
2009 Jan
Retrospective analysis of titanium plate-retained prostheses placed after total rhinectomy.
2009 Jan-Feb
Patents

Sample Use Guides

Levomethorphan (dissolved in a mixed solution of 5% Emulphor™ EL-620/5% ethanol/90% isotonic sodium chloride solution, 2.5 mg/mL, rat 4–6) was administered to male DA pigmented rats, which were 5 weeks old and around 90 g mean weight. The drugs were given once daily at 5 mg/kg by intraperitoneal injection for ten successive days.
Route of Administration: Intraperitoneal
Liver microsomes from individual male dark agouti (DA) rats (n=4, 6 weeks old, around 125 g mean weight) were prepared by ultracentrifugation. For the in vitro experiments with rat and human liver microsomes, the reaction mixture consisted of 0.1 M potassium phosphate buffer (pH 7.4) with an NADPH generating system (1.3 mM NADP, 3.3 mM G-6-P, 0.4 U/ mL G-6-PDH, 3.3 mM MgCl2), 50 μM substrate (dextromethorphan or levomethorphan), and 0.5 mg protein/mL microsomes (rat or human liver microsomes) in a final volume of 200 μL. Dextromethorphan and levomethorphan were dissolved in methanol, and the final concentration of the organic solvent was 0.1%. The incubation was started by adding the microsomal fraction and then continued for 0, 5, 10, or 20 min. The reaction was terminated by adding an equal volume of a mixed organic solution of 50% acetonitrile and 50% methanol, including 10 μM levallorphan (IS), and vigorous shaking.
Name Type Language
LEVOMETHORPHAN
INN   MI  
INN  
Official Name English
IDS-NL-004
Preferred Name English
LEVOMETHORPHAN [MI]
Common Name English
levomethorphan [INN]
Common Name English
L-METHORPHAN
Common Name English
LEVOMETHORPHAN SOLUTION [USP-RS]
Common Name English
(-)-3-METHOXY-N-METHYLMORPHINAN
Systematic Name English
2H-10,4A-IMINOETHANOPHENANTHRENE, 1,3,4,9,10,10A-HEXAHYDRO-6-METHOXY-11-METHYL-
Systematic Name English
IDS-NL-005
Code English
MORPHINAN, 3-METHOXY-17-METHYL-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
DEA NO. 9210
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
Code System Code Type Description
EVMPD
SUB08478MIG
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
WIKIPEDIA
LEVOMETHORPHAN
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
INN
148
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
CHEBI
146176
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
NCI_THESAURUS
C83875
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-751-7
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
EPA CompTox
DTXSID20872403
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
FDA UNII
7ZZ22K9QE6
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
ChEMBL
CHEMBL1908323
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
MERCK INDEX
m6790
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY Merck Index
SMS_ID
100000082278
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
CAS
125-70-2
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
PUBCHEM
5362449
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY
RS_ITEM_NUM
1362359
Created by admin on Mon Mar 31 18:19:11 GMT 2025 , Edited by admin on Mon Mar 31 18:19:11 GMT 2025
PRIMARY